1-20 of 21
Nadia Harbeck
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study

Patrick Neven, Nicole Stahl, Maria Vidal, Miguel Martín, Peter A. Kaufman, Nadia Harbeck, Kelly K. Hunt, Stacey Carter, Francois-Clement Bidard, Peter A. Fasching, Philippe Aftimos, Duncan Wheatley, Erika Hamilton, Rebecca Aft, Swati Kulkarni, Peter Schmid, Manali Bhave, Roohi Ismail-Khan, Claudia Karacsonyi, Shawn T. Estrem, Bastien Nguyen, Umut Ozbek, Eunice Yuen, Vanessa Rodrik-Outmezguine, Eva Ciruelos
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5304–5313.
https://doi.org/10.1158/1078-0432.CCR-24-2113
Published: 02 December 2024
View article titled, A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Open the PDF for A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study in another window
Includes: Supplementary data
Journal Articles

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer, Matthias Christgen, Jenci Palatty, Sherko Kuemmel, Eva-Maria Grischke, Doris Augustin, Michael Braun, Jochem Potenberg, Rachel Wuerstlein, Katja Krauss, Claudia Schumacher, Helmut Forstbauer, Toralf Reimer, Andrea Stefek, Hans Holger Fischer, Enrico Pelz, Christine zu Eulenburg, Ronald Kates, Hua Ni, Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Hans Heinrich Kreipe, Ulrike Nitz, Nadia Harbeck
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 805–814.
https://doi.org/10.1158/1078-0432.CCR-22-1587
Published: 16 February 2023
View article titled, Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> Trial
Open the PDF for Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> Trial in another window
Includes: Supplementary data
Journal Articles

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, Aleix Prat, Matthias Christgen, Sherko Kuemmel, Mohammad Parsa Mohammadian, Daniel Gebauer, Ronald Kates, Laia Paré, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Rachel Wuerstlein, Monika Graeser, Enrico Pelz, Katarzyna Jóźwiak, Christine zu Eulenburg, Hans Heinrich Kreipe, Nadia Harbeck, on behalf of the ADAPT TN investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4995–5003.
https://doi.org/10.1158/1078-0432.CCR-22-0482
Published: 14 November 2022
View article titled, De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Open the PDF for De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial in another window
Includes: Supplementary data
Journal Articles

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O'Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3433–3442.
https://doi.org/10.1158/1078-0432.CCR-22-0305
Published: 15 August 2022
View article titled, Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Open the PDF for Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study in another window
Includes: Supplementary data
Journal Articles

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 851–859.
https://doi.org/10.1158/1078-0432.CCR-21-3032
Published: 01 March 2022
View article titled, Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Open the PDF for Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis

Sara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, Chiara Gargiuli, Loris De Cecco, Evandro de Azambuja, Debora Fumagalli, Christos Sotiriou, Nadia Harbeck, Miguel Izquierdo, Paolo Nuciforo, Jens Huober, Vera Cappelletti, Saverio Cinieri, Martine Piccart, Maria Grazia Daidone, Giancarlo Pruneri, Mario Paolo Colombo, Elda Tagliabue, Paolo Verderio, Serena Di Cosimo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6307–6313.
https://doi.org/10.1158/1078-0432.CCR-21-1600
Published: 01 December 2021
View article titled, Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Open the PDF for Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis in another window
Includes: Supplementary data
Journal Articles

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

Ioannis A. Vathiotis, Myrto K. Moutafi, Prajan Divakar, Thazin Nwe Aung, Tao Qing, Aileen Fernandez, Vesal Yaghoobi, Sarra El-Abed, Yingbo Wang, Sebastien Guillaume, Paolo Nuciforo, Jens Huober, Serena Di Cosimo, Sung-Bae Kim, Nadia Harbeck, Henry Gomez, Saba Shafi, Konstantinos N. Syrigos, George Fountzilas, Christos Sotiriou, Lajos Pusztai, Sarah Warren, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6156–6163.
https://doi.org/10.1158/1078-0432.CCR-21-2103
Published: 15 November 2021
View article titled, Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer
Open the PDF for Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

David Venet, Mattia Rediti, Marion Maetens, Debora Fumagalli, David N. Brown, Samira Majjaj, Roberto Salgado, Lajos Pusztai, Nadia Harbeck, Sarra El-Abed, Yingbo Wang, Cristina Saura, Henry Gomez, Vladimir Fedorovich Semiglazov, Evandro de Azambuja, Jens Huober, Paolo Nuciforo, Serena Di Cosimo, Martine Piccart, Sherene Loi, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5607–5618.
https://doi.org/10.1158/1078-0432.CCR-21-1317
Published: 15 October 2021
View article titled, Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
Open the PDF for Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

Gino M. Dettorre, Saoirse Dolly, Angela Loizidou, John Chester, Amanda Jackson, Uma Mukherjee, Alberto Zambelli, Juan Aguilar-Company, Mark Bower, Christopher C. T. Sng, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Ricard Mesia, Ailsa Sita-Lumsden, Elia Seguí, Federica Biello, Daniele Generali, Salvatore Grisanti, Pavetha Seeva, Gianpiero Rizzo, Michela Libertini, Antonio Maconi, Charlotte Moss, Beth Russell, Josep Tabernero, Nadia Harbeck, Bruno Vincenzi, Rossella Bertulli, Diego Ottaviani, Andrea Marrari, M. Carmen Carmona-García, Neha Chopra, Carlo Tondini, Oriol Mirallas, Valeria Tovazzi, Vittoria Fotia, Claudia A. Cruz, Nadia Saoudi-Gonzalez, Eudald Felip, Lorenza Scotti, Alvin J. X. Lee, Thomas Newsom-Davis, Andrea Patriarca, Lorenza Rimassa, Armando Santoro, Alessandra Gennari, Mieke Van Hemelrijck, Nikolaos Diamantis, David J. Pinato
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6_Supplement): S01-03.
https://doi.org/10.1158/1557-3265.COVID-19-21-S01-03
Published: 15 March 2021
View article titled, Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score
Journal Articles

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer

John F.R. Robertson, Abigail Evans, Stephan Henschen, Cliona C. Kirwan, Ali Jahan, Laura M. Kenny, J. Michael Dixon, Peter Schmid, Ashutosh Kothari, Omar Mohamed, Peter A. Fasching, Kwok-Leung Cheung, Rachel Wuerstlein, Danielle Carroll, Teresa Klinowska, Justin P.O. Lindemann, Alexander MacDonald, Richard Mather, Rhiannon Maudsley, Michele Moschetta, Myria Nikolaou, Martine P. Roudier, Tinnu Sarvotham, Gaia Schiavon, Diansong Zhou, Li Zhou, Nadia Harbeck
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (16): 4242–4249.
https://doi.org/10.1158/1078-0432.CCR-19-3387
Published: 14 August 2020
View article titled, A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>−</sup> Primary Breast Cancer
Open the PDF for A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>−</sup> Primary Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer

Richard S. Finn, Yuan Liu, Zhou Zhu, Miguel Martin, Hope S. Rugo, Véronique Diéras, Seock-Ah Im, Karen A. Gelmon, Nadia Harbeck, Dongrui R. Lu, Eric Gauthier, Cynthia Huang Bartlett, Dennis J. Slamon
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (1): 110–121.
https://doi.org/10.1158/1078-0432.CCR-19-0751
Published: 03 January 2020
View article titled, Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer
Open the PDF for Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

Martin Filipits, Urania Dafni, Michael Gnant, Varvara Polydoropoulou, Margaret Hills, Astrid Kiermaier, Evandro de Azambuja, Denis Larsimont, Federico Rojo, Giuseppe Viale, Masakazu Toi, Nadia Harbeck, Kathleen I. Prichard, Richard D. Gelber, Phuong Dinh, Dimitrios Zardavas, Brian Leyland-Jones, Martine J. Piccart-Gebhart, Mitch Dowsett
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (13): 3079–3086.
https://doi.org/10.1158/1078-0432.CCR-17-3473
Published: 01 July 2018
View article titled, Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study
Open the PDF for Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study in another window
Includes: Supplementary data
Journal Articles

High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab

Maurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, Jeff Sperinde, Dominique Agbor-Tarh, Christine Campbell, Ahmed Chenna, John Winslow, Violeta Serra, Josep Lluis Parra, Ludmila Prudkin, José Jimenez, Claudia Aura, Nadia Harbeck, Lajos Pusztai, Catherine Ellis, Holger Eidtmann, Joaquin Arribas, Javier Cortes, Evandro de Azambuja, Martine Piccart, José Baselga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (3): 569–576.
https://doi.org/10.1158/1078-0432.CCR-14-1824
Published: 01 February 2015
View article titled, High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Open the PDF for High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab in another window
Includes: Supplementary data
Journal Articles

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

Gail D. Lewis Phillips, Carter T. Fields, Guangmin Li, Donald Dowbenko, Gabriele Schaefer, Kathy Miller, Fabrice Andre, Howard A. Burris, III, Kathy S. Albain, Nadia Harbeck, Veronique Dieras, Diana Crivellari, Liang Fang, Ellie Guardino, Steven R. Olsen, Lisa M. Crocker, Mark X. Sliwkowski
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (2): 456–468.
https://doi.org/10.1158/1078-0432.CCR-13-0358
Published: 16 January 2014
View article titled, Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Open the PDF for Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy in another window
Includes: Supplementary data
Journal Articles

DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy

Oliver Hartmann, Frédérique Spyratos, Nadia Harbeck, Dimo Dietrich, Anne Fassbender, Manfred Schmitt, Serenella Eppenberger-Castori, Vincent Vuaroqueaux, Florence Lerebours, Katrin Welzel, Sabine Maier, Achim Plum, Stephan Niemann, John A. Foekens, Ralf Lesche, John W.M. Martens
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 315–323.
https://doi.org/10.1158/1078-0432.CCR-08-0166
Published: 31 December 2008
View article titled, DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy
Open the PDF for DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy in another window
Includes: Supplementary data
Journal Articles

A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer

Antonio Llombart-Cussac, Miguel Martin, Nadia Harbeck, Rodica M. Anghel, Alexandra E. Eniu, Mark W. Verrill, Patrick Neven, Jacques De Grève, Allen S. Melemed, Romnee Clark, Lorinda Simms, Christopher J. Kaiser, Doreen Ma
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3652–3659.
https://doi.org/10.1158/1078-0432.CCR-06-2377
Published: 15 June 2007
View article titled, A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer
Open the PDF for A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer in another window
Journal Articles

Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients

Julia Dorn, Manfred Schmitt, Ronald Kates, Barbara Schmalfeldt, Marion Kiechle, Andreas Scorilas, Eleftherios P. Diamandis, Nadia Harbeck
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1742–1748.
https://doi.org/10.1158/1078-0432.CCR-06-2482
Published: 15 March 2007
View article titled, Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients
Open the PDF for Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients in another window
Journal Articles

Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer

Carla A. Borgoño, Tadaaki Kishi, Andreas Scorilas, Nadia Harbeck, Julia Dorn, Barbara Schmalfeldt, Manfred Schmitt, Eleftherios P. Diamandis
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (5): 1487–1493.
https://doi.org/10.1158/1078-0432.CCR-05-2106
Published: 06 March 2006
View article titled, Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer
Open the PDF for Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer in another window
Journal Articles

Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals

Katharina Seck, Silvia Riemer, Ronald Kates, Tobias Ullrich, Verena Lutz, Nadia Harbeck, Manfred Schmitt, Marion Kiechle, Robert Diasio, Eva Gross
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 5886–5892.
https://doi.org/10.1158/1078-0432.CCR-04-1784
Published: 22 August 2005
View article titled, Analysis of the <em>DPYD</em> Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals
Open the PDF for Analysis of the <em>DPYD</em> Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals in another window
Journal Articles

Detection and Clinical Implications of Early Systemic Tumor Cell Dissemination in Breast Cancer

Klaus Pantel, Volkmar Müller, Margherita Auer, Nathalie Nusser, Nadia Harbeck, Stephan Braun
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (17): 6326–6334.
Published: 24 December 2003
View article titled, Detection and Clinical Implications of Early Systemic Tumor Cell Dissemination in Breast Cancer
Open the PDF for Detection and Clinical Implications of Early Systemic Tumor Cell Dissemination in Breast Cancer in another window